Table 2.
Patients who reported at least some problems on individual EQ-5D dimensions at baseline and 16 weeks
| EQ-5D dimension | Number (%) of patients | |||||
|---|---|---|---|---|---|---|
| Placebo qw | Dupilumab 300 mg qw | Dupilumab 300 mg q2w | ||||
| Baseline, n = 459 | Week 16, n = 423 | Baseline, n = 462 | Week 16, n = 431 | Baseline, n = 457 | Week 16, n = 440 | |
| Mobility | ||||||
| No problems | 380 (82.8) | 364 (86.1) | 364 (79.0) | 406 (94.2)a | 367 (80.3) | 407 (92.5)b |
| Some problems | 75 (16.3) | 58 (13.7) | 92 (20.0) | 25 (5.8)a | 87 (19.0) | 33 (7.5)b |
| Confined to bed | 4 (0.9) | 1 (0.2) | 5 (1.1) | 0 | 3 (0.7) | 0 |
| Self-care | ||||||
| No problems | 389 (84.7) | 374 (88.4) | 399 (86.6) | 415 (96.3)a | 386 (84.5) | 417 (94.8)c |
| Some problems | 70 (15.3) | 49 (11.6) | 60 (13.0) | 16 (3.7)a | 69 (15.1) | 22 (5.0)c |
| Unable to do | 0 | 0 | 2 (0.4) | 0 | 2 (0.4) | 1 (0.2) |
| Usual activities | ||||||
| No problems | 245 (53.4) | 294 (69.5) | 247 (53.6) | 370 (85.8)a | 268 (58.6) | 374 (85.0)a |
| Some problems | 191 (41.6) | 119 (28.1) | 192 (41.6) | 58 (13.5)a | 171 (37.4) | 64 (14.5)a |
| Unable to do | 23 (5.0) | 10 (2.4) | 22 (4.8) | 3 (0.7) | 18 (3.9) | 2 (0.5)b |
| Pain/discomfort | ||||||
| No problems | 97 (21.1) | 166 (39.2) | 84 (18.2) | 268 (62.2)a | 87 (19.0) | 273 (62.0)a |
| Some problems | 254 (55.3) | 225 (53.2) | 274 (59.4) | 156 (36.2)a | 283 (61.9) | 163 (37.0)a |
| Extreme pain/discomfort | 108 (23.5) | 32 (7.6) | 103 (22.3) | 7 (1.6)a | 87 (19.0) | 4 (0.9)a |
| Anxiety/depression | ||||||
| No problems | 231 (50.3) | 273 (64.5) | 227 (49.2) | 316 (73.3)b | 236 (51.6) | 329 (74.8)b |
| Some problems | 194 (42.3) | 131 (31.0) | 201 (43.6) | 110 (25.5) | 193 (42.2) | 107 (24.3)b |
| Extremely anxious or depressed | 34 (7.4) | 19 (4.5) | 33 (7.2) | 5 (1.2)a | 28 (6.1) | 4 (0.9)b |
EQ-5D 5-dimension 3-level EuroQol, qw once weekly, q2w every 2 weeks
a P ≤ 0.0001, b P < 0.05, and c P < 0.001 vs. placebo at 16 weeks using Fisher’s exact test